Agilent receives fda companion diagnostic approval for ki-67 ihc mib-1 pharmdx in high-risk early breast cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced its ki-67 ihc mib-1 pharmdx (dako omnis) is now fda approved as an aid in identifying patients with early breast cancer (ebc) at high risk of disease recurrence, for whom adjuvant treatment with verzenio® (abemaciclib) in combination with endocrine therapy is being considered. this is the first ihc assay measuring ki-67 expression to receive fda approval in the context of treatment with verzenio and was de
A Ratings Summary
A Quant Ranking